Assessment and diffusion of medical innovations in France: an overview
- PMID: 29686802
- PMCID: PMC5907634
- DOI: 10.1080/20016689.2018.1458575
Assessment and diffusion of medical innovations in France: an overview
Abstract
Background: In France, a significant part of health expenditure is publicly funding. This put a heavy burden on society. In an economic context requiring tight control of public spending, it seems relevant to control the diffusion of medical innovations. That is why health technology assessment is subject to an increasing interest at national level for management and approval decisions. This article provides an overview of the assessment and diffusion of medical innovation in France. Method: The data are extracted from French authorities or organisations websites and documents and from French legislative texts. In addition, regarding discussion, a search in MEDLINE database was carried out. Results: An overview of the assessment and diffusion of medical innovation in France is given by presenting the different types of medical innovations according to French health system definition (I); introducing French authorities participating to health technology assessment and describe assessment procedures of medical innovations (II); and giving details about market access process of innovative health product in France (III). Key opportunities and challenges of medical innovation assessment and diffusion in France are discussed at the end of this article. Conclusion: In France, medical innovation is considered as a crucial component for quality of care and performance of healthcare system. The aim of health technology assessment is to promote a secure and timely access to innovation for patients. Nevertheless, it appears necessary to improve regulatory mechanisms.
Keywords: Innovation; decision making; health care; health technology assessment; market access; pharmacoeconomics.
Figures
Similar articles
-
Assessing Definitions and Incentives Adopted for Innovation for Pharmaceutical Products in Five High-Income Countries: A Systematic Literature Review.Pharmaceut Med. 2023 Jan;37(1):53-70. doi: 10.1007/s40290-022-00457-5. Epub 2023 Jan 17. Pharmaceut Med. 2023. PMID: 36648749 Free PMC article.
-
Market access pathways for cell therapies in France.J Mark Access Health Policy. 2015 Nov 18;3. doi: 10.3402/jmahp.v3.29094. eCollection 2015. J Mark Access Health Policy. 2015. PMID: 27123176 Free PMC article.
-
[Innovation funding schemes and the structuring of health economic evaluation in France].Therapie. 2023 Sep 22:S0040-5957(23)00120-8. doi: 10.1016/j.therap.2023.09.003. Online ahead of print. Therapie. 2023. PMID: 37821312 French.
-
Evidence use in decision-making on introducing innovations: a systematic scoping review with stakeholder feedback.Implement Sci. 2017 Dec 4;12(1):145. doi: 10.1186/s13012-017-0669-6. Implement Sci. 2017. PMID: 29202772 Free PMC article. Review.
-
[The French health care funding system for research and innovation in oncology].Bull Cancer. 2018 Jun;105(6):581-595. doi: 10.1016/j.bulcan.2018.03.006. Epub 2018 May 7. Bull Cancer. 2018. PMID: 29747854 Review. French.
Cited by
-
Understanding the Effects of Iatrogenic Management on Population Health: A Medical Innovation Perspective.China CDC Wkly. 2023 Jul 7;5(27):614-618. doi: 10.46234/ccdcw2023.118. China CDC Wkly. 2023. PMID: 37476618 Free PMC article. No abstract available.
-
Cost-effectiveness of infant hypoallergenic formulas to manage cow's milk protein allergy in France.J Mark Access Health Policy. 2022 Dec 10;11(1):2154418. doi: 10.1080/20016689.2022.2154418. eCollection 2023. J Mark Access Health Policy. 2022. PMID: 36518150 Free PMC article.
-
How innovation can be defined, evaluated and rewarded in health technology assessment.Health Econ Rev. 2022 Jan 3;12(1):1. doi: 10.1186/s13561-021-00342-y. Health Econ Rev. 2022. PMID: 34981266 Free PMC article. Review.
-
The Assessment of the Innovativeness of a New Medicine in Italy.Front Med (Lausanne). 2021 Dec 8;8:793640. doi: 10.3389/fmed.2021.793640. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34957163 Free PMC article.
-
Multiple criteria decision analysis approach to consider therapeutic innovations in the emergency department: The methoxyflurane organizational impact in acute trauma pain.PLoS One. 2020 Apr 15;15(4):e0231571. doi: 10.1371/journal.pone.0231571. eCollection 2020. PLoS One. 2020. PMID: 32294125 Free PMC article.
References
-
- INSEE Tableaux de l’Économie Française Edition 2017 [Internet]. 2016. [cité 2017 Mai 14]. Disponible sur:https://www.insee.fr/fr/statistiques/2569384?sommaire=2587886#graphique-...
-
- Ministère des Solidarités et de la Santé Le forfait innovation - Prise en charge de l’innovation par la DGOS : de la recherche clinique à la diffusion aux patients [Internet]. 2017. [cité 2017 Août 6]. Disponible sur: http://social-sante.gouv.fr/systeme-de-sante-et-medico-social/recherche-...
-
- OECD Oslo manual 3rd edition [Internet]. 2005. [cité 2017 Déc 3]. Disponible sur:http://www.oecd-ilibrary.org/docserver/download/9205111e.pdf?expires=151...
-
- Instruction n°DGOS/PF4/2014/33 du 28 janvier 2014 relative au programme de recherche translationnelle, au programme hospitalier de recherche clinique, au programme de recherche médico-économique, au programme de recherche sur la performance du système de soins, au programme de recherche infirmière et paramédicale, pour l’année 2014 [Internet] http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire... Disponible sur:
-
- INAHTA INAHTA [Internet]. 2017. [cité 2017 September14]. Disponible sur:http://www.inahta.org
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources